China's National Medical Products Administration (NMPA) has approved Keymed Biosciences’ supplemental new drug application ...

Based on the results of the FLAMES study, the National Medicines Products Administration (NMPA) has approved the new drug application for Senaparib. The Wee1 inhibitor IMP7068 and the ATR ...

China NMPA approves Sanofi’s Sarclisa for patients with newly diagnosed multiple myeloma ineligible for transplant: Paris Saturday, February 1, 2025, 12:00 Hrs [IST] The Nationa ...

002755.SZ), jointly announce that China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) of limertinib for the treatment of adult patients with locally ...

is pleased to announce that Senaparib Capsules (派舒宁 ® ）has received marketing authorization in China from National Medical Products Administration (NMPA) as monotherapy for the maintenance treatment ...